FGFR1 and non-small cell lung carcinoma: In EGFR mutant non-small cell lung cancer (NSCLC), where genetic and epigenetic mechanisms can lead to drug resistance and cause EGFR tyrosine kinase inhibitors (TKIs) failure, FGFR1 has been selected as the best target to re-sensitize cells to EGFR inhibition and contrast EMT-related adaptive resistance [88].